Skip to content

Multi-center Study of Deep Learning AI in Breast Mass

A Multi-center Study of Breast Mass Screening and Diagnosis Using Deep Learning AI-based on Real-time Ultrasound Examination

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05443672
Enrollment
1122
Registered
2022-07-05
Start date
2021-08-12
Completion date
2023-08-31
Last updated
2022-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms

Brief summary

This multi-center study intends to evaluate the value of the detection and differential diagnosis of breast mass using deep learning AI-based real-time ultrasound examination.

Detailed description

As the most common cancer expected to occur all over the world, extensive population screening plays a very important role in the early diagnosis and prognosis of the breast cancer. X-ray and ultrasound are the most commonly used screening methods, and ultrasound is especially important for Asian women with dense breasts. However, ultrasound is greatly affected by the operator's skill and experience, and the diagnostic accuracy varies greatly. Artificial intelligence (AI) is a new method emerging in recent years, active in many medical fields and can effectively improve the diagnostic efficiency. However, previous researches on the application of AI in ultrasound are focused on single or multi-modality static ultrasound images. This multi-center study intends to evaluate the value of the detection and differential diagnosis of breast mass using deep learning AI-based real-time ultrasound examination.

Interventions

DEVICEYizhun BUSMS

During the breast scanning, Yizhun BUSMS uses different color box to identify the breast lesion, and the box color indicates the risk grade of the lesion.

Sponsors

Peking Union Medical College Hospital
CollaboratorOTHER
Peking University Cancer Hospital & Institute
CollaboratorOTHER
Peking University Third Hospital
CollaboratorOTHER
Guangdong Provincial Hospital of Traditional Chinese Medicine
CollaboratorOTHER
Third Affiliated Hospital of Zhengzhou University
CollaboratorOTHER
Hebei Medical University Fourth Hospital
CollaboratorOTHER
Henan Cancer Hospital
CollaboratorOTHER_GOV
Shanxi Province Cancer Hospital
CollaboratorOTHER
First Affiliated Hospital Xi'an Jiaotong University
CollaboratorOTHER
Chongqing University Cancer Hospital
CollaboratorOTHER
Anqing Hospital affiliated to Anhui Medical University
CollaboratorUNKNOWN
Qinhuangdao Maternal and Child Health Care Hospital
CollaboratorOTHER
The First Affiliated Hospital of Xiamen University
CollaboratorOTHER
Anyang Tumor Hospital
CollaboratorOTHER
The Third Affiliated Hospital of Jinzhou Medical University
CollaboratorUNKNOWN
General Hospital of Jincheng Coal Industry Group
CollaboratorUNKNOWN
Suzhou First People's Hospital
CollaboratorUNKNOWN
Peking University
CollaboratorOTHER
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

1. Females who undergo ultrasound examination for a complaint of breast lesion; 2. The breast lesion that will obtain definite pathological diagnosis or follow-up at least two years.

Exclusion criteria

1. The breast lesion that has received CNB or FNA; 2. The breast cancer patient who has received neoadjuvant chemotherapy.

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic performance of breast mass using deep learning AI-based real-time ultrasound examination12 monthsPathology as a gold standard, to evaluate the diagnostic performance (sensitivity, specificity and accuracy)

Countries

China

Contacts

Primary ContactYong Wang
drwangyong77@163.com13391817899

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026